Skip to main content
NIH funding notice PA-18-014

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional)

Closed on January 7, 2020.

Posted
November 3, 2017
Close date
January 7, 2020
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $390,217 in first-year total cost, median $195,109.

Most frequent study sections

  1. Health Services Organization and Delivery Study Section[HSOD]2

Most frequent institutions

  1. COLUMBIA UNIVERSITY HEALTH SCIENCES1
  2. NORTHWESTERN UNIVERSITY AT CHICAGO1
Competing awards under PA-18-014 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Delays in Acquisition of Oral Antineoplastic Agents1R21CA242044-01A1HERSHMAN, DAWNCOLUMBIA UNIVERSITY HEALTH SCIENCES, NY$189,338HSOD
2019Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients with Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to THerapY: TheEMPATHY Pilot Study1R21CA230367-01A1CELLA, DAVIDEFFICACE, FABIONORTHWESTERN UNIVERSITY AT CHICAGO, IL$200,879HSOD

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.